The US Food and Drug Administration (FDA) has approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster) in adults aged ≥50 years.
Indications: Shingrix is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged ≥50 years. It is not indicated for prevention of primary varicella infection (chickenpox).
Dosage and administration: Administer 2 doses (0.5 mL each) at 0 and 2 to 6 months.
Adverse reactions: Solicited local adverse reactions in subjects aged ≥50 years were pain, redness, and swelling. Solicited general adverse reactions were myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms.
Shingrix approved in the US for prevention of shingles in adults aged 50 and over. [news release]. London, UK: GlaxoSmithKline plc; October 23, 2017. http://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/. Accessed October 24, 2017.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22
FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23